Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Abstract

Objectives: Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol.

Design and methods: Because there is a paucity of data on the effect of statins on serum prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n = 22) compared with placebo (n = 18) on circulating scruin prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia.

Results: Fluvastatin treatment decreased total cholesterol (P < 0.05), LDL-cholesterol (P < 0.01), hs-CRP (P < 0.05) and serum prohepcidin levels (P < 0.05) significantly.

Conclusion: Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.